Sep 08, 2021 / 01:45PM GMT
Neena Marie Bitritto-Garg - Citigroup Inc., Research Division - VP & Analyst
Good morning, everybody, and thank you for attending Citi's 16th Annual Biopharma Conference. I'm Neena Bitritto-Garg, one of the biotech analysts here, and I'm pleased to be joined this morning by the management team from Prothena. So I have with me today, President and CEO, Gene Kinney; and CFO and COO, Tran Nguyen. And we're planning to cover a range of topics from the Company's kind of recent shift in focus to Alzheimer's programs as well as the other wholly owned programs in birtamimab and the partnered portfolio.
And before we get into the formal discussion, I just wanted to note that, if you have any questions during the discussion, feel free to e-mail me directly or [send some] questions through the online portal, they'll come to me, and I'll try and incorporate them as time permits.
So now I just want to turn it over to Gene for some opening remarks.
Gene G. Kinney - Prothena Corporation plc - President, CEO & Director
Well, thanks,
Prothena Corporation PLC at Citi BioPharma Conference (Virtual) - Fireside Chat Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
